The table below shows C4 Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$29.94M
-$33.28M
-$18.12M
-$33.13M
-$26.60M
-$24.93M
Capital expenditure
$64.00K
$0.00
$0.00
$589.00K
$172.00K
$421.00K
Investing cash flow
$16.15M
$29.13M
-$53.40M
$53.53M
-$4.00M
-$61.73M
Dividends paid
-
-
-
-
CCCC operating cash flow (10-K history)
C4 Therapeutics, Inc. reported operating cash flow of -$98.69M for fiscal year 2025. That is down 51.5% from -$65.16M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $55.61M (FY 2019) to -$98.69M. Figures come from the company's audited annual reports as filed with the SEC.